Compare Gilead Sciences, Inc. (GILD) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vistra Corp — how do they compare? Gilead Sciences, Inc. trades at $134.68 (market cap $163.51B), while Vistra Corp trades at $151.3 (market cap $54.03B). The key difference: Gilead Sciences, Inc. is far larger — about 3× Vistra Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | VST | |
|---|---|---|
Market Cap | $163.51B | $54.03B |
Sector | Health | Technology |
52-Week High | $155.80 | $217.92 |
52-Week Low | $108.22 | $134.71 |
Enterprise Value | $178.05B | $75.78B |
Dividend Yield | 2.49% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Vistra Corp. (VST) trades at $152.50, down 3.74% amid broader market volatility, but maintains strong analyst support with a 90.91% buy rating. The stock shows bullish technical signals with support at $148 and resistance at $165, while fundamentals reveal robust profitability with 11.52% net income margin and 74.92% ROE. Recent earnings beat expectations in Q1 2026, and the company benefits from long-term power purchase agreements with major tech firms.
Outlook remains positive given Vistra's strategic focus on renewables and AI-driven power demand, though investors face risks from power-price volatility and high debt. The consensus price target of $253.00 implies significant upside potential, supported by institutional confidence and resilient cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
